Harald Polzer

The target landscape of clinical kinase drugs

Susan Klaeger, Stephanie Heinzlmeir, Mathias Wilhelm et al. · Science · 2017 · 871 citations · Full text

Medicine, Oncology, Pharmacology +15

Activating FLT3 Mutants Show Distinct Gain-of-Function Phenotypes In Vitro and a Characteristic Signaling Pathway Profile Associated with Prognosis in Acute Myeloid Leukemia

Hanna Janke, Friederike Pastore, Daniela Schumacher et al. · PLoS ONE · 2014 · 70 citations · Full text

Medicine, Genetics, Oncology +17

Exome sequencing identifies recurring FLT3 N676K mutations in core-binding factor leukemia

Sabrina Opatz, Harald Polzer, Tobias Herold et al. · Blood · 2013 · 52 citations

Medicine, Genetics, Molecular Genetics +14

Breakdown of the FLT3-ITD/STAT5 Axis and Synergistic Apoptosis Induction by the Histone Deacetylase Inhibitor Panobinostat and FLT3-Specific Inhibitors

Kristin Pietschmann, Hella Anna Bolck, Marc Buchwald et al. · Molecular Cancer Therapeutics · 2012 · 48 citations

Medicine, Cancer Biology, Oncology +17

Targeting FLT3 with a new-generation antibody-drug conjugate in combination with kinase inhibitors for treatment of AML

Maike Roas, Binje Vick, Marc‐André Kasper et al. · Blood · 2022 · 35 citations · Full text

Pharmacy, Medicinal Chemistry, Oncology +17